Oral Cancer News

Advanced type of cancer radiation reduces side effects, but impact on controlling cancer is unclear

Source: www.sunherald.com Author: press release An advanced type of cancer radiation is more successful than traditional radiation in avoiding "dry mouth" when treating head and neck cancers, but it is unknown whether the treatment is better or worse at reducing the size of tumors, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality. The report finds that intensity-modulated radiation therapy (IMRT) leads to fewer cases of xerostomia, commonly known as dry mouth, than other types of radiation. Xerostomia, a potential side effect to radiation when salivary glands are damaged, can affect basic functions like chewing, swallowing and breathing; senses such as taste, smell and hearing; and can significantly alter a patient's appearance and voice. However, the report did not find evidence that IMRT is more successful than any other kind of radiation therapy in reducing tumors. Many scientists consider IMRT to be theoretically better able to target cancerous cells while sparing healthy tissues, but more research is needed, the report said. The comparative effectiveness review, Comparative Effectiveness and Safety of Radiotherapy Treatments for Head and Neck Cancer, was authored by the Blue Cross and Blue Shield (BC/BS) Association, Technology Evaluation Center in Chicago. "The development of new technologies to treat cancer has been one of the true success stories of American medical research," said AHRQ Director Carolyn M. Clancy, M.D. "This report provides patients and their doctors with more information about these advances, which they can use to make more informed choices about [...]

Oral Cancer Foundation News Team - A2010-05-27T21:12:29-07:00May, 2010|Oral Cancer News|

Clinical outcomes for T1-2N0-1 oral tongue cancer patients underwent surgery with and without postoperative radiotherapy

Source: 7thspace.com Authors: Su Jung Shim et al. Background: The aim of this study was to assess the results of curative surgery with and without radiotherapy in patients with T1-2N0-1 oral tongue squamous cell carcinoma (OSCC) and to evaluate survival and prognostic factors. Methods: Retrospective analysis of 86 patients with T1-2N0-1 OSCC who received surgery between January 2000 and December 2006. Fourteen patients (16.3%) received postoperative radiotherapy (PORT). Patient characteristics, tumor characteristics, treatment modality, failure patterns, and survival rates were analyzed. Results: The median follow-up was 45 months. The five-year overall survival (OS) and disease-free survival (DFS) rates were 80.8% and 80.2%, respectively. Higher tumor grade and invasion depth [greater than or equal to] 0.5 cm were the significant prognostic factors affecting five-year OS and DFS (OS rate; 65% vs. 91%, p = 0.001 for grade; 66% vs. 92%, p = 0.01 for invasion depth: DFS rate; 69% vs. 88%, p = 0.005 for grade; 66% vs. 92%, p = 0.013 for invasion depth). In the risk group, there was no local failure in patients with postoperative radiotherapy. Conclusions: In T1-2N0-1 OSCC, factors that affected prognosis after primary surgery were higher tumor grade and deep invasion depth over 0.5 cm. Postoperative radiotherapy should be considered in early oral tongue cancer patients with these high-risk pathologic features. Authors: Su Jung Shim, Jihye Cha, Woong Sub Koom, Gwi Eon Kim, Chang Geol Lee, Eun Chang Choi, Ki Chang Keum Source: Radiation Oncology 2010, 5:43

Oral Cancer Foundation News Team - A2010-05-27T07:56:08-07:00May, 2010|Oral Cancer News|

Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer

Source: Stanford University Author: Staff Departments of Radiation Oncology and Medical Oncology, and Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre; University of Melbourne, Melbourne, Australia; Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Radiation Oncology, Hospital General Vall d'Hebron, Barcelona, Spain; Department of Radiation Oncology, University of Massachusetts Medical Center, North Worcester, MA; Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, FL; Department of Radiation Oncology, Genolier Swiss Medical Network, Geneva, Switzerland; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France; Quality Assurance Review Center, Providence, RI. PURPOSE To report the impact of radiotherapy quality on outcome in a large international phase III trial evaluating radiotherapy with concurrent cisplatin plus tirapazamine for advanced head and neck cancer. PATIENTS AND METHODS The protocol required interventional review of radiotherapy plans by the Quality Assurance Review Center (QARC). All plans and radiotherapy documentation underwent post-treatment review by the Trial Management Committee (TMC) for protocol compliance. Secondary review of noncompliant plans for predicted impact on tumor control was performed. Factors associated with poor protocol compliance were studied, and outcome data were analyzed in relation to protocol compliance and radiotherapy quality. Results At TMC review, 25.4% of the patients had noncompliant plans but none in which QARC-recommended changes had been made. At secondary review, 47% of noncompliant plans (12% overall) had deficiencies with a predicted major adverse impact on tumor control. Major deficiencies were unrelated to tumor subsite or to T or N stage (if N+), [...]

Charlotte Parker2010-05-27T07:47:24-07:00May, 2010|Oral Cancer News|

Swedish Match snuff separates from snus pack

Source: Tobacco News Author: Staff Swedish Match North America, maker of moist snuff, cigars and chewing tobacco, is taking a different approach to marketing its Swedish-style snus tobacco product when compared to two other U.S. tobacco companies offering the product, according to a report by the Richmond Times-Dispatch. Swedish Match marketers began a sampling effort in Vail, Colo., and now are handing out silvery sample packs of General Snus on Wall Street — a sign that the product will be positioned as a high-end item, the report stated.”We are emphasizing the Swedish cachet,” Richard Flaherty, president of Swedish Match North America, told the paper when asked about the sampling push. In addition, Swedish Match’s General brand is more expensive than either the Marlboro brand by Altria Group’s Philip Morris unit, or Reynolds American’s Camel brand. The premium positioning is not the only difference in its marketing strategy.”We’re not marketing snus as something for when you can’t smoke. We’re marketing it as an alternative to cigarettes,” Flaherty said in the report. The company is looking for smokers who don’t want to smoke at all, rather than using the product as a fill-in to cigarettes, the report stated. For this reason, the company identified a key target group in parents who worry about secondhand smoke at home, Flaherty said. In addition, the focus on niche consumer groups rather than the general tobacco market is a reason why General isn’t appearing in convenience stores. Instead of fighting for shelf space with two of the toughest competitors in [...]

Charlotte Parker2010-05-27T07:48:07-07:00May, 2010|Oral Cancer News|

Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study

Source: Oxford Journals Author: Dr A. L. Finn Abstract Background: Fentanyl buccal soluble film (FBSF) has been developed as a treatment of breakthrough pain in opioid-tolerant patients with cancer. The objective of this study was to evaluate the efficacy of FBSF at doses of 200–1200 μg in the management of breakthrough pain in patients with cancer receiving ongoing opioid therapy. Patients and methods: This was a multicenter, randomized, double-blind, placebo-controlled, multiple-crossover study that included opioid-tolerant adult patients with chronic cancer pain who experienced one to four daily episodes of breakthrough pain. The primary efficacy assessment was the sum of pain intensity differences at 30 min (SPID30) postdose. Results: The intent-to-treat population consisted of 80 patients with ≥1 post-baseline efficacy assessment. The least-squares mean (LSM ± SEM) of the SPID30 was significantly greater for FBSF-treated episodes of breakthrough pain than for placebo-treated episodes (47.9 ± 3.9 versus 38.1 ± 4.3; P = 0.004). There was statistical separation from placebo starting at 15 min up through 60 min (last time point assessed). There were no unexpected adverse events (AEs) or clinically significant safety findings. Conclusions: FBSF is an effective option for control of breakthrough pain in patients receiving ongoing opioid therapy. In this study, FBSF was well tolerated in the oral cavity, with no reports of treatment-related oral AEs.

Charlotte Parker2010-05-26T10:45:17-07:00May, 2010|Oral Cancer News|

Environmental cancer risks may be more dangerous than you think

Source: LA Times Author: Jill U Adams Pollutants and other chemicals in your environment — your home, your frontyard, your workplace — may be more toxic to your health than you know, according to a report released earlier this month. The President's Cancer Panel, an advisory group charged with monitoring the war on cancer, proposed in its May 5 report that environmental chemicals might contribute to a larger share of deaths from cancer than the 1% to 5% figure cited by the National Cancer Institute. Skeptical reactions to the report, most notably from the American Cancer Society, say that the report's focus on potential environmental risks may distract from known risks with much larger effects, such as smoking, sun exposure, diet and exercise. But others, such as David Kriebel, an epidemiologist at the University of Massachusetts at Lowell who testified before the panel in 2008, say the risks associated with environmental exposures are unclear and could easily be larger than assumed. "Isn't it disappointing that we don't know how much larger?" he asks. "It is always worth making the point that tobacco is the most important exposure to try to eliminate," but that message shouldn't preclude investigation of other exposures, says Shelia Hoar Zahm, deputy director of cancer epidemiology and genetics at the National Cancer Institute. The report, with its focus on the admittedly incomplete science on environmental cancer risks, helps the U.S. government to keep the broad picture in mind as it continues its war on cancer, she says. [...]

Charlotte Parker2010-05-25T15:17:24-07:00May, 2010|Oral Cancer News|

FDA tobacco chief says to industry: ‘Long way to go’

Source: Associated Press Staff: Michael Felberbaum WILLIAMSBURG, Va. — The head of the government's tobacco regulator says the Food and Drug Administration's new power to regulate tobacco is a promising tool to reduce the toll of disease and death caused by tobacco use. "This is an opportunity for me to serve my country by preventing its men, women and children from suffering and dying from tobacco-related diseases," Dr. Lawrence Deyton, director of the FDA's Center for Tobacco Products told attendees Monday at the Tobacco Merchants Association annual meeting in Williamsburg, Va. Deyton, who has held the job for about nine months, said his job is to address the "enormous toll of confusion, suffering and death caused by the current state of tobacco use in this country." "And frankly, we have a long way to go," he said. Deyton said his top priorities include stopping kids from picking up the habit, educating the public and applying standards based on science. While Deyton encouraged an open dialogue with the industry, he acknowledged that some believe regulation as a threat to the tobacco business and will "try and block FDA at every turn in implementing this law." For those who ignore the law, Deyton said, the FDA has multiple options to enforce compliance and the agency will "not hesitate to take these steps when warranted." The FDA's authority granted last June is the main area of discussion at the two-day gathering of tobacco manufacturers, growers and retailers. The agency is tasked with creating [...]

Charlotte Parker2010-05-25T13:27:43-07:00May, 2010|Oral Cancer News|

Nano-bio-chip checks for oral cancer

Source: www.nanotech-now.com Author: press release The gentle touch of a brush on the tongue or cheek can help detect oral cancer with success rates comparable to more invasive techniques like biopsies, according to preliminary studies by researchers at Rice University, the University of Texas Health Science Centers at Houston and San Antonio and the University of Texas M.D. Anderson Cancer Center. A new test that uses Rice's diagnostic nano-bio-chip was found to be 97 percent "sensitive" and 93 percent specific in detecting which patients had malignant or premalignant lesions, results that compared well with traditional tests. The results of this study, which was led by John McDevitt, were published in the journal Cancer Prevention Research. Oral cancer afflicts more than 300,000 people a year, including 35,000 in the United States alone. The five-year survival rate is 60 percent, but if oral cancer is detected early, that rate rises to 90 percent. "One of the key discoveries in this paper is to show that the miniaturized, noninvasive approach produces about the same result as the pathologists do," said Dr. McDevitt, whose group developed the novel nano-bio-chip technology. Dr. McDevitt and his team are working to create an inexpensive chip that can differentiate premalignant lesions from the 95 percent of lesions that will not become cancerous. The minimally invasive technique would deliver results in 15 minutes instead of several days, as lab-based diagnostics do now. Instead of an invasive, painful biopsy, the new procedure requires just a light brush of the lesion [...]

Oral Cancer Foundation News Team - A2010-05-23T16:01:08-07:00May, 2010|Oral Cancer News|

Boehringer Ingelheim will announce preliminary data in the area of head and neck cancer

Source: pr-usa.net Author: press release Boehringer Ingelheim will announce preliminary data in the areas of head and neck cancer and non-small cell lung cancer (NSCLC) for one of the company's investigational compounds, BIBW 2992. These data will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. BIBW 2992 is an orally-administered small molecule under development that irreversibly inhibits the epidermal growth factor receptor (EGFR/HER1) and human epidermal receptor 2 (HER2) tyrosine kinases. BIBW 2992 data in head and neck cancer(1) New data will report preliminary best response analysis for 74/109 patients from an ongoing Phase 2 study of 124 patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) who did not respond to platinum-containing therapy. In this study, patients were initially randomly assigned to either BIBW 2992 or cetuximab. Twenty-two percent of the 34 patients receiving BIBW 2992 experienced reduction in tumor size (measured as partial response), compared to 13 percent of the 40 patients receiving cetuximab. Preliminary safety analyses revealed diarrhea and skin-related adverse events as the most common adverse events associated with BIBW 2992. "Metastatic head and neck cancer has a very poor prognosis, and patients are in desperate need for new treatment options," says Tanguy Y. Seiwert, M.D., lead investigator of the trial, University of Chicago Medical Center. "These findings, while preliminary, are encouraging and warrant further investigation of BIBW 2992 in head and neck cancer."

Oral Cancer Foundation News Team - A2010-05-23T12:55:48-07:00May, 2010|Oral Cancer News|

UConn scientist may have way to detect pre-tumor cancer

Source: www.theday.com Author: staff A University of Connecticut researcher thinks he might have found a way to find cancer even before it reveals itself in a tumor or other symptoms. Jim Rusling, professor of chemistry and cell biology at the UConn Health Center, has been working with colleagues at the National Institutes of Health to detect specific proteins found in the blood of those with prostate or oral cancer. These biomarker proteins are detectable in early stages of these cancers, so the researchers believe they can be used for earlier detection and prevention than is now possible. Rusling noted that the approach has an advantage over genetic testing, because that can only assess the risk of getting the disease, whereas measuring biomarkers can reveal the actual presence cancer. He described the project, funded by a $1.5 million NIH grant, in a recent issue of Analytical Chemistry.

Oral Cancer Foundation News Team - A2010-05-21T07:26:05-07:00May, 2010|Oral Cancer News|